<DOC>
	<DOCNO>NCT01351090</DOCNO>
	<brief_summary>This randomize , double blind , placebo-controlled study subject undergone major surgery . Each subject 's study participation consist screen visit , 2-day treatment period , follow-up visit . Following surgery , subject randomly assign receive intranasally ( IN ) ketorolac 10 mg , IN ketorolac 30 mg , placebo pain intensity ( PI ) rating equal least 40 100-mm visual analog scale ( VAS ) . Thereafter , subject receive study drug every 8 hour , last dose give 40 hour . For pain relieve study drug , subject access morphine sulfate ( MS ) administer via patient control analgesia ( PCA ) . The primary objective evaluate analgesic efficacy multiple intranasal ( IN ) dose ketorolac 2 day . The secondary objective evaluate safety tolerability dose regimen .</brief_summary>
	<brief_title>Study Safety , Tolerability Analgesic Efficacy Multiple Doses Ketorolac Tromethamine ( IN ) Postoperative Pain</brief_title>
	<detailed_description />
	<mesh_term>Pain , Postoperative</mesh_term>
	<mesh_term>Ketorolac</mesh_term>
	<mesh_term>Ketorolac Tromethamine</mesh_term>
	<mesh_term>Analgesics</mesh_term>
	<criteria>Men woman , age 18 year old Body weight &gt; = 100 pound ( 45.4 kg ) &lt; = 300 pound ( 136.1 kg ) Women childbearing potential must negative serum pregnancy test result prior entry study Able provide write informed consent At least moderate pain determine PI score &gt; = 40 mm 100mm VAS Expected remain hospital least 48 hour Willing able comply test requirement define protocol Willing able complete posttreatment visit Allergy sensitivity ketorolac ethylene diamine tetraacetic acid ( EDTA ) Allergic reaction aspirin nonsteroidal antiinflammatory drug ( NSAIDs ) Current upper respiratory tract infection respiratory tract condition could interfere absorption nasal spray assessment adverse event Use IN product within 24 hour prior study entry Clinically significant abnormality screen laboratory test History cocaine use result nasal mucosal damage Active peptic ulcer disease , recent ( define within 6 month ) gastrointestinal bleeding perforation , history peptic ulcer disease gastrointestinal bleeding Advanced renal impairment risk renal failure due volume depletion A history clinically significant medical problem , opinion investigator would interfere study participation Participation within 30 day study entry within 5 time halflife , whichever longer , another investigational drug study Allergy significant reaction opioids Pregnancy breastfeed Previous participation study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
</DOC>